OMERS ADMINISTRATION Corp Invests $508,000 in IDEAYA Biosciences, Inc. $IDYA

Key Points

• OMERS ADMINISTRATION Corp acquired a new stake in IDEAYA Biosciences, Inc. by purchasing 31,000 shares valued at approximately $508,000.
• Major institutional investors, such as CWM LLC and Signaturefd LLC, have significantly increased their stakes in the company, indicating growing interest in IDEAYA Biosciences.
• Analysts have mixed ratings for IDEAYA, with nine giving it a Buy rating and a consensus price target of $47.10, despite recent earnings results showing a loss.

OMERS ADMINISTRATION Corp acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 31,000 shares of the company's stock, valued at approximately $508,000.

Other large investors also recently added to or reduced their stakes in the company. CWM LLC increased its stake in IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after acquiring an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock worth $39,000 after acquiring an additional 1,546 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in IDEAYA Biosciences during the fourth quarter worth approximately $47,000. Signaturefd LLC increased its stake in IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after acquiring an additional 2,271 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in IDEAYA Biosciences by 46.4% during the first quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $109,000 after acquiring an additional 2,112 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA traded down $1.70 during mid-day trading on Monday, hitting $25.46. The stock had a trading volume of 394,332 shares, compared to its average volume of 1,134,234. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $37.80. The firm has a market cap of $2.23 billion, a PE ratio of -6.77 and a beta of 0.12. The company has a 50 day moving average of $23.66 and a two-hundred day moving average of $20.63.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. During the same quarter last year, the firm posted ($0.68) earnings per share. The business's revenue was up NaN% compared to the same quarter last year. Equities research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Citigroup started coverage on IDEAYA Biosciences in a research note on Thursday. They set an "outperform" rating on the stock. TD Cowen started coverage on IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a "buy" rating for the company. Wells Fargo & Company started coverage on IDEAYA Biosciences in a research report on Thursday, June 26th. They set an "overweight" rating and a $44.00 target price for the company. The Goldman Sachs Group upgraded IDEAYA Biosciences to a "hold" rating and set a $25.00 target price for the company in a research report on Thursday, July 10th. Finally, JPMorgan Chase & Co. boosted their price target on IDEAYA Biosciences from $72.00 to $74.00 and gave the company an "overweight" rating in a report on Wednesday, September 3rd. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.77.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.